Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 10, 2017. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing details acquisitions of ordinary shares under the Company's ShareReward Plan executed on February 9, 2017.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.8336 per share.
- Transaction Volume per Executive: 16 shares (comprising 8 partnership shares and 8 matching shares).
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine equity compensation acquisitions by senior management.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific share purchases.
Important Facts for Investors
- Executive Participation: Ten senior executives, including CEO Sir Andrew Witty and CEO Designate Ms. E. Walmsley, acquired shares on the same date.
- Transaction Nature: All transactions were acquisitions under the ShareReward Plan, indicating standard equity compensation vesting or matching rather than open-market purchases.
- Scale of Transactions: The volume per individual (16 shares) is nominal, suggesting these are likely matching shares or vesting events rather than significant personal capital deployment.
- Valuation Context: The share price of £15.8336 reflects the market value on February 9, 2017.